BioNTech SE (Nasdaq: BNTX) has released the initial results from its AHEAD-MERIT Phase 2/3 clinical trial, which is assessing the efficacy of its investigational mRNA cancer immunotherapy BNT113.
This trial is specifically examining BNT113 in combination with pembrolizumab against pembrolizumab alone as a first-line treatment for patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) that express PD-L1.
HPV16 is a prevalent high-risk type of HPV linked to cancer, and it is associated with approximately one-third of HNSCC cases.
The Phase 3 segment of the AHEAD-MERIT trial focuses on two primary endpoints: progression-free survival and overall survival, which are crucial indicators of clinical benefit.
Currently, there are no approved treatments specifically targeting HPV-positive tumors, despite their unique characteristics.
Many patients with HPV16-positive HNSCC face disease progression with existing standard treatments, highlighting the urgent need for innovative HPV-targeted therapies that can enhance long-term survival.
Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech, stated, “The potential of mRNA cancer immunotherapies in combination regimen lies in their ability to induce immune responses that may translate into durable clinical benefit and, ultimately, prolonged survival of patients. While the PFS result was not statistically significant at this first analysis, the data support continued evaluation of BNT113 plus pembrolizumab in this trial and show that it is engaging its intended therapeutic mechanism.”